Prizes and awards

Adamed amongst 10 Most Innovative Pharmaceutical Companies 2016

1 July 2016

Gazeta Finansowa conducted an analysis of the most innovative solutions among companies from the pharmaceutical sector in Poland. Adamed Group, with its flagship project ONCO-3CLA, was awarded a place among the 10 Most Innovative Pharmaceutical Companies of 2016.

The aim of ONCO-3CLA is to develop a novel biotechnological molecule which neutralises neoplastic cells while not damaging healthy cells in the patient’s body. The programme was created through a proprietary technology platform for the development of a special carrier – a guidance system for cells. ONCO-3CLA is co-financed by the European Union, from the European Regional Development Fund.

ONCOTRAIL, a continuation of the ONCO-3CLA project, is aimed at conducting phase 1 clinical trials of the targeted biotechnological molecule developed by Adamed Group’s R&D Department and at establishing Poland’s first clinical trial centre for conducting early phase oncological trials. The project is implemented by a consortium including the Maria Skłodowska-Curie Institute of Oncology, Adamed Group, Institute of Haematology and Transfusion Medicine, Medical Centre for Postgraduate Education and Institute of Mother and Child. It is co-financed under the STRATEGMED programme.

CSR/Corporate social responsibility
9 June 2016